Monoamine oxidase inhibitors in rheumatoid arthritis - Anti-tumor necrosis factor? [1]

International Journal of Immunopharmacology

Volumn 22, Issue 11, 2000, Pages 1007-1008

  Altschuler, Eric Lewin ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC AMP; MONOAMINE OXIDASE INHIBITOR; TUMOR NECROSIS FACTOR;

CROHN DISEASE; DRUG MECHANISM; HUMAN; LETTER; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS;

ARTHRITIS, RHEUMATOID; HUMANS; MONOAMINE OXIDASE INHIBITORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0033772966     PISSN: 01920561     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0192-0561(00)00047-3     Document Type: Letter

References (10)

1. Remission of rheumatoid arthritis and other disorders of immunity in patients taking monoamine oxidase inhibitors
2. Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial
3. Molecular pharmacology of the β-adrenergic receptor on THP-1 cells
4. Characterization of cAMP-dependent inhibition of LPS-induced TNF α production by rolipram, a specific phosphodiesterase IV (PDE IV) inhibitor
5. Catecholamines increase monocyte TNF receptors and inhibit TNF through β 2 adrenoreceptor activation
6. Release of tumor necrosis factor-α from coronary smooth muscle: activation of NF-κB and inhibition by elevated cyclic AMP
7. The antidepressant rolipram suppresses cytokine production and prevents autoimmune encephalomyelitis
8. Amelioration of collagen II-induced arthritis in rats by the type IV phosphodiesterase inhibitor Rolipram
9. Randomised controlled trial of CDP571 antibody to tumour necrosis factor-α in Crohn's disease
10. Crohn's disease remission with phenelzine treatment